CURRICULUM VITAEYi-Zarn Wang BDS, MD, FACS

Current Title: Professor of SurgeryBusiness Address: 200 West Esplanade, Suite 200

Kenner, LA 70065Business Telephone and Fax: (504) 464-8500/Office; (504) 464-8525/FaxBusiness email Address: ywang@lsuhsc.edu

Birthplace: Taiwan, Republic of ChinaCitizenship: U.S.A (Naturalization date: 2/11/1998)

Education:Undergraduate1974-1980 Kaohsiung Medical College, School of Dentistry

Kaohsiung, Taiwan, Rep. of ChinaB.D.S (Equivalent to D.D.S)

Graduate/Medical1982-1986 Oregon Health Sciences University

Graduate/Residency Program, Portland, ORCertificate in Oral Pathology

1986-1990 Oregon Health Sciences University School of MedicinePortland, ORM.D.

Internship1990-1991 Washington University School of Medicine/Barnes Hospital

General Surgery

Residency1991-1994 Washington University School of Medicine/Barnes Hospital

General Surgery

Post-Doctoral Fellowship1982-1986 Oral Pathology Resident

Oregon Health Sciences University, School of DentistryPortland, OR

1984-1985 General Pathology ResidentOregon Health Sciences University, School of DentistryPortland, OR

1987 Department of Anatomic PathologyVeteran Administration Medical CenterPortland, OR

Clinical Fellowship1980-1981 Hospital Dentist Residency

The Air Force General HospitalTaipei, Taiwan, Rep. of China

Certification:1990 National Board of Medical Examiners, #3877412/14/1995 Diplomat of the American Board of Surgery

#39992, Recertified 10/17/2004

Licensure:Louisiana, #10961R, 7/31/2013Missouri, #106189, Expired

Academic, Professional, and Research Appointments:1982 -1984 Teaching Assistant, Department of Pathology, School of Dentistry,

Oregon Health Sciences University, Portland, OR 1984-1985 Instructor, Patient Evaluation Clinic, Department of Clinical Pathology,

School of Dentistry, Oregon Health Sciences University, Portland, OR 

1985 -1986 Lecturer, Sophomore General Pathology, Department of Pathology, School of Dentistry, Oregon Health Sciences University, Portland, OR

 1985 -1986 Pathology Lab Instructor, Department of Pathology, School of Dentistry,

Oregon Health Sciences University, Portland, OR

1985 -1986 Research Fellow, Department of Immunology, School of DentistryThe Oregon Health Sciences University, Portland, OR

 1990-1991 Clinical Assistant Professor, Department of Pathology,

School of Dentistry, Oregon Health Sciences University, Portland, OR

1990 -1994 Teaching Assistant, Department of SurgeryWashington University School of Medicine, St. Louis, MO

1994 -1995 Instructor of Surgery, Department of SurgeryLouisiana State University Medical Center, School of MedicineNew Orleans, LA

 1995 -2001 Assistant Professor of Surgery, Department of Surgery

Louisiana State University Health Sciences Center, School of MedicineNew Orleans, LA

 2001 - 2005 Associate Professor of Surgery, Department of Surgery

Louisiana State University Health Sciences Center, School of MedicineNew Orleans, LA

2002- 2005 Director of Surgical Education, Department of Surgery Louisiana State University Health Sciences Center, School of MedicineNew Orleans, LA

 2002- 2005 Chief, Division of General Surgery, Department of Surgery

Louisiana State University Health Sciences Center, School of MedicineNew Orleans, LA

2005- 2006 Visiting surgeon and teaching staff, Department of Surgery, VAMC/Baylor College of Medicine, Houston, TX

07/2006- Associate Professor, Department of Surgery, Louisiana State University 6/2010 Health Sciences Center, School of Medicine

New Orleans, LA

10/2006- Staff Surgeon, Neuroendocrine Tumor Clinic, Ochsner-Kenner Medical Present Center, Kenner, LA

7/2010- Professor of Surgery, Department of Surgery, Louisiana State UniversityPresent Health Sciences Center, School of Medicine

New Orleans, LA

Membership in Professional Organizations: American College of Surgeons: Fellow James D. Rives Surgical Society: MemberSurgical Association of Louisiana: MemberThe Society for Surgery of the Alimentary Tract: MemberThe Society of Laparoendoscopic Surgeons: MemberAmerican Society of Colon and Rectal Surgeons: MemberAmerican Hepato-Pancreato-Biliary Association: MemberSociety of Surgical Oncology: MemberAmerican Association of Endocrine Surgeons: Member

Awards and Honors:1974 -1980 Scholarship sponsored by the Taiwan Sugar Corporation

 1974 -1980 Scholarship from The Taiwan National Teacher’s Association 1980 “Award of Kaohsiung Medical College Alumina Association in Japan”

Received at my commencement from Kaohsiung Medical College, School of Dentistry

1982 -1985 Teaching Assistant Scholarship, Sponsored by Department of Pathology,School of Dentistry, Oregon Health Sciences University, Portland, OR

TEACHING EXPERIENCE AND RESPONSIBILITIES Course/Clerkship/Residency or Fellowship/CME Directorships

I was appointed as the course director of the weekly Basic Science and Clinical Surgical Review Conferences and was in charge of weekly teaching conferences from 11/1996 to 9/2005. I reviewed different surgical topics with the residents and students every week. I was appointed Director of Surgical Education from 4/2002 until 12/2005. I was selected to be the speaker at the weekly conferences more than 90% of the time, at the request of residents. The residents’ in-service exam score averages improved from 33 percentile before I assumed the teaching assignment, to greater than 55 percentile after I became the course director and weekly lecturer. The in-service exam scores remained above 50 percentile for

seven years in a row and during that time I was nominated for a teaching award every year. Additionally, the residents named the weekly conference “Wang’s Conference,” which was approved by Department head.  On my own time, I engage in detailed discussions about different General Surgery/Oncologic Surgery topics with individual residents who need reinforcement of his or her knowledge base in clinical application, in-service, and board examination preparations. Each graduating chief resident whom I worked with has passed their board exam. I have also helped several chief residents who already graduated prepare for their third and last chance to pass the boards, which they all did.

Curriculum Development/ImplementationOnce I was put in charge of the weekly teaching conferences, I changed the teaching format. My method involved a group discussion that was centered around one central topic and a set of well-organized questions I generated weekly to complement this topic. This style of teaching was different from the traditional lectures with handouts or slide presentations. The discussions were designed to merge the basic science concepts with clinical practice, and to move from the easy questions (to which the students and junior residents should know the answers) to those questions that even chief residents would struggle with.

Weekly, with one chosen topic, we began with simple questions in the area of anatomy and normal physiology, then moved on to a set of slightly more complex patho-physiology questions and finally to differential diagnosis and clinical workup. These discussions led to questions of appropriate treatment options, surgical versus nonsurgical approaches, operative intervention and possible expected and unexpected intra-operative findings, and finally the way to handle these different intra-operative observations. Conferences concluded with questions related the patients’ post–operative care including potential complications, follow-up visits and preventative processes including family member screenings.

This new format was well received by the students and residents. It was clearly reflected by the unmarked evaluations submitted by the residents biannually.

Creation of Enduring Teaching MaterialsMy lecture notes have been stored in many residents' personal computers and are still being passed from residents to residents.

Departmental/Interdisciplinary Teaching ConferencesI routinely participate in the weekly grand rounds and M&M conferences. I attend the weekly multidisciplinary tumor conference and function as moderator.

At the conclusion of clinic activities, I always review interesting and important subjects in detail with the residents and students pertaining to patient conditions that we encountered. Many times, I review multiple topics in one afternoon. Two days a week, I perform surgery on oncology patients with residents and students. I routinely conduct extensive teaching in the operating room while waiting for induction of anesthesia and/or during operation.

 Three times a week, I conduct bedside rounds with students and residents; each round lasts about two hours to assure that we may have detailed discussion on different topics related to patient care.

Teaching Awards:1996 Runner-up Aesculapiaan Society Teaching Award, Louisiana State

University Health Sciences Center, New Orleans, LA 

1997- 1999 Candidate for Allen Copping Teaching Award, Louisiana StateUniversity Health Sciences Center, New Orleans, LA

 2001 Semi-Finalist for the Allen Copping Teaching Award, Louisiana State

University Health Sciences Center, New Orleans, LA 2003 Winner of the Allen Copping Teaching Award, Louisiana State

University Health Sciences Center, New Orleans, LA

2006 Nominee for Allen Copping Teaching Award, Louisiana State University Health Sciences Center, New Orleans, LA

The residents have continued to nominate me yearly, although I am no longer eligible to be the award recipient since 2006.

RESEARCH AND SCHOLARSHIP Grants and Contracts:

Funded 1999 - 2004 Co-investigator, NCT00003782 - A Three-Arm Randomized Trial

to Compare Adjuvant Adriamycin/Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes. Sponsor: NSABP

2000 - 2002 Co-investigator, NCT00004931 - A Clinical Trial Comparing 5-Fluoriuracil (5FU) Plus Leucovorin (LV) and Oxaliplatin

with 5-FU plus LV for the Treatment of Patients with Stages II and III Carcinoma of the Colon.

Sponsor: NCI    2000 – 2004 Co-investigator, NCT00009945 - A Clinical Trial Comparing

Adjuvant Clodronate Therapy vs. Placebo In Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or

Tamoxifen or No Therapy.Sponsor: NSABP

  

   2000 - 2005 Co-investigator, NCT00004067 - A randomized trial comparing the

safety and efficacy of Adriamycin and Cyclophosphamide followed by Taxol (AC-T) to that of Adriamycin and Cyclophosphamide

followed by Taxol plus Herceptin (AC-T+H) in Node Positive Breast Cancer Patients who have Tumors that over express HER2. Sponsor: NSABP

  2001-2002 Co-investigator, NCT00389987- A Prospective, Multicenter,

Double –Blind with In-House blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults. Sponsor: Merck

2001 - 2002 Co-Investigator, NCT0034476- A Phase IIb Study to Determine the

Efficacy and Safety of LY315920 in Patients with Severe Sepsis. Sponsor: Eli Lilly and Company

2001 - 2003 Co-investigator, NCT0016432 - A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating The Effect of Exemestane in Clinical Stage T1-3 N0-1M0 Postmenopausal breast Cancer Patients Completing At Least Five Years of Tamoxifen Therapy -and- Bone Mineral Density, Biochemical Markers, and Lipid (BBL) Sub-Study of NSABP B-33.Sponsor: NSABP

 2001 - 2004 Co-investigator, NCT00619710- A Multicenter, Randomized,

Double Blind, Comparative Trial of Intravenous MerremTM

(meropenem, ICI 119,660) vs Primaxin® I.V. (imipenem-cilastatin) in the Treatment of Hospitalized subjects with Complicated Skin and Skin Structure Infections. Sponsor: Astra Zeneca

  2002 – 2005 Co-Investigator, NCT00229112- A Prospective, Multicenter,

Double- Blind With In house Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults. Sponsor: Merck

2003 – 2009 Co-Investigator, NCT00053898 – A Clinical Trial Comparing Astrozole with

Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy. Sponsor: NSABP

 2004 – 2005 Co-Investigator, NCT00087178– A Clinical Trial of Adjuvant

Therapy Comparing Six Cycles of 5-Fluroouracil, Epirubicin and Cyclophosphamide [FEC] to four Cycles of

Adriamycin and Cyclophosphamide [AC], with or without Celecoxib, in Patients with Node-Negative Breast Cancer.

Sponsor: NSABP 

2004 – 2008 Co-Investigator, NCT00093795 – A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regiments in Woman with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC→P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC→PG). Sponsor: NSABP

2004 – 2009 Primary/Co-Investigator, NCT00784849 (IND 70,627)- Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy with Radiolabeled Methylene Blue. Sponsor: LSU Health Sciences Center New Orleans

2006 - 2011 Co-Investigator, NCT00363051- An Open Label, Stratified, Single-Arm Phase II study of RAD001 in patients with Advanced

Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy.

Sponsor: Novartis Pharmaceuticals 

2007 - 2010 Co-Investigator, NCT00412061- A Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase III study in Patients

with Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10mg/day or Octreotide Depot and Placebo. Sponsor: Novartis Pharmaceuticals

 2007 - 2010 Co-Investigator, NCT00510068- A Randomized, Double-Blind,

Phase III study of RAD001 10mg/day Plus Best Supportive Care versus Placebo Plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocrine Tumor (NET). Sponsor: Novartis Pharmaceuticals

2009 - 2011 Co-Investigator, NCT00781911- A Phase 2, Multicenter, Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well- or Moderately- Differentiated Carcinoid or Islet Cell Carcinoma. Sponsor: ImClone LLC

2012 - Co-Investigator. Outcomes in Surgical Oncology: A Multi-Center Database. Sponsor: University of Louisville

2012 - Co-Investigator. The Caris Registry.Sponsor: Caris Science, Inc

Journal Publications: Refereed

1. Bullock WW, Wang YZ, Gabler WL, and Creamer HR. Aggregate human colostral sIgA stimulates delayed, non-complement-dependent NBT

reduction by human neutrophils. Inflammation 1989, 13(1):67-78.2. Wang, YZ. Surgical intervention for hyperparathyroidism: preoperative

localization with/without intraoperative localization/biological PTH assay versus surgeon’s brain and hands. Current Surgery 1995, 52(1):15-20.

3. Wang, YZ, Flattman G., Steeb G., O’Leary J.P. Surgical management of perforated duodenal ulcer. Surgical Rounds 1998, Supplement (11):4-11.

4. Steeb G., Wang Y.Z., O’Leary J.P. Management of perforated peptic ulcers. Hospital Practice special report 1998.

5. Wang Y, Wang S: Automation of clinical and patient records. Southern Medical Journal 1999, 92(1): 16-22.

6. Meyers MO, Gagliardia AR, Flattmann JG, Wang YZ, and Woltering EA. Suramin Analogues Inhibit Human Angiogenesis In Vitro. Journal of Surgical Research, 2000, 91(2): 130-134.

7. Steeb G, Wang YZ, Siegrist B, O’Leary JP. Infections within the peritoneal cavity: a historical perspective. Am Surg 2000, 66(2):98-104.

8. Hunt JP, Wright MJ, Steeb G., Wang YZ, Buechter KJ, Meyer AA, Baker CC. Accuracy of administrative data in trauma: splenic injuries as an example. J. Trauma 2000, 49(4): 679-686.

9. Wynn A., Wise M, Wright MJ, Rafaat A, Wang Y, Steeb G, McSwain N, Buechter KJ, Hunt JP. Accuracy of Administrative & Trauma Registry databases. J Trauma 2001, 51;464-8.

10. Wang YZ, and Wang S. The digital signature technology for health care applications. Southern Medical Journal, 2001, 94(3): 281-6.

11. Phelan H, Hunt J, and Wang YZ: Management of retrohepatic caval injury. Southern Medical Journal, 2001, 94(7); 728-31.

12. Jung SP, Siegrist B, Hornick CA, Wang YZ, Wade JR, Anthony CT, Woltering EA. Effect of human Recombinant Endostatin protein on Human Angiogenesis. Angiogenesis 2002, 5:111-118.

13. Duchesne JC, Wang YZ, Weintraub SL, Boyle M, Hunt JP. Stoma complications: a multivariate analysis. Am Surg. 2002, 68(11)961-6; discussion 966.

14. Maxwell IV PJ, Lewis JM, Anthony CT, Watson JC, Meyer5s MO, Espenan TD, Espenan GD, Wang YZ, Woltering EA. External Bean Radiation Therapy Does Not Inhibit the Human “Angiogenic Switch” But Decreases Endothelial Cell Growth and Angiogenic Vessel Development. Ann Surg Onc, 2003: 10:1, S49.

15. Woltering EA, Lewis JM, Maxwell PJ, Frey DJ, Wang YZ, Rothermel J, Anthony CT, Balster DA, O’Leary JP, Harrison LH. Development of a Novel in Vitro Human Tissue-Based Angiogenesis Assay to Evaluate The Effect of Antiangiogenic Drugs. Annals of Surgery, 2003, 237(6);790-800.

16. Lewis JM, Grafton LH, Maxwell IV PJ, Martin LF, Nesbit LT, Wang Y-Z, Woltering EA. Development of an Architecturally-Intact Human Skin-Based Angiogenesis Model. JACS Suppl, 2003, 197:3, S57.

17. Cooke HJ, Wang YZ, Wray D, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Christofi FL, Gosh P, O’Dorisio TM. A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in the guinea pig colon. Regulatory Peptides, 2003, 114(1); 51-60.

18. Siegrist B, Anthony CT, Hornick C, Wade MR, Jung SP, Wang YZ and

Woltering EA. Effect of human Angiostatin protein on human angiogenesis in vitro. Angiogenesis. 2003, 6(3): 233-40.

19. Ghanami R, Obeid L, Buchert B, Beech S, Wang YZ, Lopez FA. Clinical case of the month. Expanding abdominal mass in a 41-year-old patient with a history of alcohol abuse. J La State Med Soc. 2004, 156(4):181-5.

20. Lewis JM, Maxwell IV PJ, Anthony CT, Gebhardt BM, Thompson JL, Rothermel J, McSheehy P, Wang YZ, Woltering EA. Epothilone B is a More Potent Antiangiogenic than Paclitaxel in a Human Tumor-Based Angiogenesis Model. JACS, Suppl. 2004, 199: S90.

21. Gulec SA, Weintraub S, Wang YZ, Cundiff J, Albarado R, Moulder P, O'Leary JP, Hunt JP. Gamma-guided diagnostic peritoneal lavage for detection of bowel perforation. Arch Surg. 2004, 139(10):1075-8.

22. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. J Surg Res. 2005,125(1):104-8.

23. Stafford SJ, Wright JL, Schwimer J, Anthony CT, Cundiff JD, Thomson JL, Wang YZ, Espenan G, Maloney T, Camp A, Woltering EA. Development of 125I-methylene blue for sentinel lymph node biopsy. J Surg Oncol. 2006,94(4):293-7.

24. Cundiff JD, Wang YZ, Espenan G, Maloney T, Camp A, Lazarus L, Stolier A, Brooks R, Torrance B, Stafford S, O'Leary JP, Woltering EA. A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsy. Ann Surg. 2007, 245(2):290-6.

25. Duchesne JC, Hunt JP, Wahl G, Marr AB, Wang YZ, Weintraub SE, Wright MJ, McSwain NE Jr. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? J. Trauma. 2008, 65(2):272-6; discussion 276-8.

26. Lyons JM III, Abergel J, Thomson J, Anthony CT, Wang YZ,  Anthony L, Boudreaux JP , Strauchen J, Idrees M, Warner R, and Woltering EA. In Vitro Chemoresistance Testing in Well-Differentiated Carcinoid Tumors. Ann Surg Oncol. 2009, 16(3): 649-655.

27. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering, EA. Lymphatic mapping helps define resection margins for midgut carcinoids. Surgery. 2009, 146(6): 993-7.

28. Wang YZ. Staged Second-Look Laparoscopy to Evaluate Ischemic Bowel. JSLS. 2009, 13(4): 560-3.

29. Wang YZ, Boudreaux JP, Dowling A, and Woltering EA. Percutaneous localization of pulmonary nodules prior to video assisted thoracoscopic surgery using Methylene blue and TC-99 ---A new modification of existing techniques. Eur J Cardiothoracic Surg. 2010, 37(1): 237-8.

30. Lyons JM III, Schwimer JE, Anthony CT, Thomson JL, Cundiff JD, Casey DT, Maccini C, Kucera P, Wang YZ, Boudreaux JP, Woltering EA. The Role of VEGF Pathways in Human Physiologic and Pathologic Angiogenesis. J. Surg. Res. 2010, 159(1): 517-27.

31. Wang YZ, Boudreaux JP, Campeau R and Woltering EA. Resolution of pulsatile tinnitus following an upper mediastinum lymph node resection. South Med J. 2010, 103(4): 374-7.

32. O’Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Wang YZ, Boudreaux JP, Vinik AI, Go VLW, Howe JR, Halfdanarson T, O’Dorisio SM, and Mamikunian G. Development of a Highly Sensitive and Specific Carboxy-terminal Human Pancreastatin Assay to Monitor

Neuroendocrine Tumor Behavior. Pancreas. 2010, 39(5): 611-6.33. Joseph S, Wang YZ, Boudreaux JP, Anthony LB, Campeau R, Raines D,

O’Dorisio TM, Go VLW, Vinik AI, Cundiff J, and Woltering EA: Neuroendocrine Tumors: Current Recommendations for Diagnosis and Surgical Management. Endocrinol Metab Clin N Am. 2011, 40(1): 205-31.

34. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R, Woltering EA. A prospective evaluation of the value of intensive pre-visit counseling in patients with neuroendocrine tumors (NETS). The Am Surg. 2012, 78(1):E43-4.

35. Wang YZ, Diebold AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. J Gastrointest Surg. 2012, 16(3):635-40

36. Anthony CT, Bastidas JG, Thomson JL, Lyons J 3rd, Lewis JM, Schwimer JE, Casey P, Abadie J, Frey DJ, Wang YZ, Boudreaux JP, Woltering EA. A study of pipeline drugs in neuroendocrine tumors. J Gastrointest Cancer. 2012, 43(2):296-304.

37. Wang YZ and MD Patrick Greiffenstein P. Foreign Body Ingestion Unmasks Latent Small Bowel Carcinoid Tumor. Case Report and Review of the Literature. Clinics and Practice 2012, 1(2).

38. Lindholm EB, Lyons J 3rd, Anthony CT, Boudreaux JP, Wang YZ, Woltering EA. Do primary neuroendocrine tumors and metastasis have the same characteristics? J Surg Res. 2012, 174(2):200-6.

39. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. J Am Coll Surg. 2012, 214(6): 1017-22.

40. Diebold AE, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, Mamikunian P, Mamikunian G, and Woltering EA. Neurokinin A Levels Predict Survival in Patients with Well Differentiated Small Bowel Neuroendocrine Tumors. Surgery. 2012, 152(6):1172-6.

41. Wang YZ, King H, and Diebold A. Cocoon formation in patients with Mid-gut neuroendocrine tumors: A rare and unrecognized final pathway. Pancreas. 2013. Epub ahead of print

42. Wang YZ, Diebold A, Boudreaux JP, Raines D, Campeau R, Anthony L and Woltering E. Surgical treatment options for rectal carcinoid cancer: Trans-anal excision Versus Low Anterior Resection with Total Mesorectal Excision. The American Surgeon. Accepted.

43. Wang YZ and Hall M. Obturator canal lymph node metastasis from rectal carcinoid tumor-Total mesorectal excision may be insufficient for some rectal carcinoids. Surgical Oncology. Submitted.

44. Wang YZ, Diebold A, Boudreaux J, Campeau R, Anthony L, Woltering EA. Ovarian Metastasis from Midgut Neuroendocrine Tumors: Incidence, Clinical Implications and Management Options. Current Project.

45. Wang YZ, Rau J, Diebold AE, Opoku-Boateng A, Boudreaux JP, and Woltering EA. Neuroendocrine Tumors (NETs) of Unknown Primary: Is Early Surgical Exploration and Aggressive Debulking Justifiable? Current project.

46. Wang YZ, Lee JY, Diebold AE, Boudreaux JP, Raines D, Campeau RJ, and Woltering EA. The Diamagnetic Effects of Peritoneal Carcinomatosis in the Prognosis of Patients with Advanced Midgut Neuroendocrine Tumors. Current project.

Book Chapters: 1. Gulec SA, Wang YZ, Reinhold RB, Doherty FJ and Mele FM. Chapter 26.

Selected Technologies in General Surgery. In O’Leary (ed)’s The Physiologic Basic of Surgery, Third edition, Lippincott Williams & Wilkins, 2002.

2. Buechter KJ, Wang YZ, Hunt JP, and Weintraub S. Chapter 9. Kinematic of Trauma. In Moore, Mattox, Feliciano (eds) Trauma, Fifth edition. McGraw Hill, 2004.

3. Weintraub SL, Wang YZ, Hunt JP, and O’Leary JP. Chapter 10. Principles of Preoperative and Operative Surgery.  Sabiston Textbook of Surgery, 17th edition. Elsevier Saunders, 2004.

Videos, Electronic Media, and Multimedia:1. “Rite of Passage” Trauma care documentary series---“Code Blue”,

Charity Hospital, New Orleans, The Learning Channel, 2001.2. “Close calls” Trauma care documentary series---“Code Blue”, Charity

Hospital New Orleans, The Learning Channel, 2002.3. “Critical Hour” Trauma care documentary series, Charity Hospital, New

Orleans, The Discovery Health Channel, 2004.4. Video presentation: Lymphatic mapping helps define resection margins

for midgut carcinoids. American College of Surgeons Clinical Congress, 2012.

5. Featured physician, Carcinoid Cancer Foundation video, "Surgery and Treatment Options: Carcinoid and Neuroendocrine Tumors," December 2012, http://youtu.be/ZQhysl6g_6E.

Inventions and Patents:1. I am the first surgeon to become proficient in a technique using radiolabeled blue dye

for one-stage sentinel lymph node biopsy for breast cancer. Cundiff JD, Wang YZ, Espenan G, Maloney T, Camp A, Lazarus L, Stolier A, Brooks R, Torrance B, Stafford S, O'Leary JP, Woltering EA. A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsy. Ann Surg. 2007, 245(2):290-6.

2. I am the first surgeon to apply the lymphatic mapping technique to define surgical resection margins, sparing the ileocecal valve when possible, for patients with midgut carcinoid cancer. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA. Lymphatic mapping helps define resection margins for midgut carcinoids. Surgery. 2009, 146(6): 993-7.

3. I invented an easy way to conduct a staged second look laparoscopy to evaluate ischemic bowel after extensive lymphadenectomy for mid gut carcinoid cancer. Wang YZ. Second-Look Laparoscopy to Evaluate Ischemic Bowel. JSLS. 2009, 13(4): 560-3.

4. I invented a new technique using both blue dye and TC-99 colloid to tattoo pulmonary nodule before video assisted thoracic surgery. Wang YZ, Boudreaux JP, Dowling A and Woltering EA. Percutaneous localisation of pulmonary nodules prior to video assisted thoracoscopic surgery using Methylene blue and TC-99 ---A new modification of existing techniques. Eur J Cardiothoracic Surg. 2010, 37(1): 237-8.

5. I am the first surgeon to discover the link between pulsatile tinnitus and external tumor compression on extra-cranial vessels and I was able to resolve this condition with a minimally invasive surgical procedure. Wang YZ, Boudreaux JP, Campeau R, and Woltering EA. Resolution of pulsatile tinnitus following an upper mediastinum lymph node resection. Southern Medical Journal. 2010, 103(4): 374-7.

6. I was the first surgeon to use radio-guided, minimally invasive surgery to address carcinoid metastasis in the lower neck and upper mediastinum.Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. J Am Coll Surg. 2012, 214(6): 1017-22.

7. I am the first surgeon to become proficient in a technique using a hand held gamma detector to facilitate cytoreduction surgeries for patients with neuroendocrine tumors.Wang YZ, Diebold A, Woltering E, King H, Boudreaux JP, Anthony LB, and Campeau R. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. J Gastrointest Surg. 2012, 16(3):635-401.

8. I am the first surgeon to use intra-operative chemotherapy for patients with advanced carcinoid cancer whose resection margin in the liver or mesentery vessels might otherwise be inadequate. Manuscript in Progress.

9. I am the first surgeon to recognize and report the unique and unusual finding of a cocoon-like formation in some long term carcinoid patients.Wang YZ, King H, Diebold A. Cocoon Formation in Patients with Midgut Neuroendocrine Tumors: A Rare and Unrecognized Final Pathway. Pancreas. Accepted.

10. I am in process of developing a treatment strategy to address carcinomatosis for neuroendocrine patients. I aim to be the first surgeon to treat such carcinomatosis with HICP. Wang YZ, Lee JY, Diebold AE, Boudreaux JP, Raines D, Campeau RJ, and Woltering EA. The Diamagnetic Effects of Peritoneal Carcinomatosis in the Prognosis of Patients with Advanced Midgut Neuroendocrine Tumors. In Progress.

Scientific Presentations:1. Flattmann G, Meyers MO, Alperinlea RC, Woltering EA and Wang Y. A

Novel Human Vascular Whole Organ Modification of the Boyden Chamber. The Society of University Surgeons Resident’s Program. Tampa, FL. (1997)

2. Wang Y-Z, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Gosh P, Cooke HF: Multi-Tyrosinated Somatostatin Analog, WOC–3B, Inhibits Histamine H2 Receptor-Mediated Cyclical Chloride Secretion in the Guinea Pig Colon. AGA. (1997)

3. Wang Y-Z, Alferes L, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Gosh P, Cooke HJ: Role of Somatostatin Receptors in Discriminating Between Mechanosensitive Release of 5-HT and PGE2 in the Initiation of Secretory Reflexes in the Guinea Pig Colon (1997)

4. Cooke HJ, Wang YZ, Alferes L, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, and Ghosh P: Release of Paracrine Mediators Initiating Secretory Reflexes is Differentially Regulated by a Somatostatin Analog in the Guinea Pig Colon. International Symposium on Regulatory Peptides. (1998)

5. Hunt J, Buechter KJ, Wang Y. Solid Organ Injuries: Liver, Spleen &

Kidney. Pediatric Trauma Conference (Statewide). New Orleans, LA. (1998)

6. Meyers MO, Gagliardia AR, Flattman GJ, Wang YZ, Woltering EA. Suramin Analogues Inhibit Human Angiogenesis in Vitro. Association for Academic Surgery Annual Meeting. (1999)

7. Hunt JP, Wright MJ, Wang Y, Steeb G, Buechter KJ, Meyer A and Baker CC. The Accuracy of Administrative Data in Trauma Spleenic Injuries as an Example. American Association for the Surgery of Trauma. Boston, MA. (1999)

8. Meyers MO, Gagliardia AR, Flattmann GJ, Wang YZ, and Woltering EA. Suramin Analogues Inhibit Human Angiogenesis in Vitro. Association for Academic Surgery, 33rd Annual Meeting. Philadelphia, PA. (1999)

9. Wynn A, Wise MW, Wright MJ, Rafaat A, Wang YZ, Steeb G, McSwain N, Buechter KJ, Hunt J. The Accuracy of Administrative and Trauma Registry Databases. East Association for Surgery of Trauma. (2001)

10. Lazarus L, Wynn S, Gordon JM, Steeb G, Wang YZ, Buechter, JK, O’Leary JP, Hunt JP. Risk Factors for Abdominal Wound Dehiscence. The Louisiana Chapter of the American College of Surgeons. New Orleans, Louisiana. (2001)

11. Lazarus L, Wynn A, Gordon JM, Steeb G, Wang YZ, Buechter KJ, O’Leary JP, Hunt JP. Risk Factors for Abdominal Wound Dehiscence. The Society of University Surgeons. Chicago, Illinois. (2001)

12. Francis DE, Anthony CJ, Wang YZ, Woltering EA. Alpha-Interferon Inhibits Human Angiogenesis, in Vitro. Society of University Surgeon’s Residents’ Program. Chicago, Illinois. (2001)

13. Masse PA, Anthony CJ, Wang YZ, Woltering EA. Bi-directional Chemoattraction: The role of vessels and tumors. Society of University Surgeon’s Residents’ Program. Chicago, Illinois. (2001)

14. Duchesne JC, Wang YZ, Weintraub SL, Boyle M, Hunt JP. Stoma Complications: A Multivariate Analysis. Presented at the Louisiana Chapter of the American College of Surgeons Annual Meeting. New Orleans, Louisiana. (2002)

15. Woltering EA, Maxwell PJ, Lewis JM, Harrison LH, Frey DJ, Wang YZ, Rothermel J, Anthony CT, O’Leary JP. Development of a novel in Vitro human tumor-based angiogenesis assay to evaluate the effect of Antiangiogenic drugs on individual patient tumors. Southern Surgical Association. (2002)

16. Maxwell IV PJ, Lewis JM, Anthony CT, Watson JC, Meyers MO, Espenan TD, Espenan GD, Wang YZ, Woltering EA. External beam radiation therapy does not inhibit the human “angiogenic switch” but decreases endothelial cell growth and angiogenic vessel development. Society of Surgical Oncology. (2003)

17. Lewis JM, Grafton LH, Maxwell IV PJ, Martin LF, Nesbitt LT, Wang YZ, Woltering EA. Development of an architecturally-intact human skin-based angiogenesis model. American College of Surgeons Surgical Forum. Chicago, IL. (2003)

18. Kaplan JL, Bronaugh H, Ortiz W, Gonzalez A, Lopera J, Hunt JP, Wang YZ, Weintraub S. Treatment of portal vein thrombosis with direct thrombolytic infusion via an operatively placed mesenteric catheter. Annual Meeting of the Southeastern Surgical Congress. (2004)

19. Lewis JM, Maxwell IV PJ, Anthony CT, Gebhardt BM, Thompson JL,

Rothermel J, McSheehy P, Wang YZ, Woltering EA. Epothilone B is a More Potent Antiangiogenic than Paclitaxel in a Human Tumor-Based Angiogenesis Model. Surgical Forum. (2004)

20. Allain BW Jr., Stafford SJ, Lewis JM, Schwimer JE, Anthony CT, Kucera PR, Maccini CA, Boudreaux JP, Frey DJ, Wang YZ, Woltering EA. In vitro analysis of the efficacy of 2-Methoxyestradiol on human tumor derived angiogenesis. LAAXS. New Orleans, LA. (2005)

21. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. Louisiana Chapter of the American College of Surgeons Convention. (2005)

22. Schwimer J, Allain B, Rosedale B, Torrance B, Frey D, Boudreaux P, Anthony CT, Anthony L, Wang YZ, Woltering EA. Effects of PTK787 on Angiogenesis in two ex-vivo models of angiogenesis. Louisiana Chapter of the American College of Surgeons Convention. (2005)

23. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Effect of Two Anti-VEGF Directed Therapies on Human Angiogenesis In Vitro. Awarded 1st Place at the Louisiana Chapter of the American College of Surgeons Convention. (2005)

24. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Not All Angiogenic Vessels Are the Same: Effect of Two Somatostatin Analogs on Human Angiogenesis In Vitro. Louisiana Chapter of the American College of Surgeons Convention. (2005)

25. Lyons III, JM, Lindholm E, Anthony LB, Wang YZ, Woltering EA, Boudreaux JP. Metastatic carcinoid causing encasement of the mesenteric vasculature should not preclude cytoreduction. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. (2008)

26. Lyons III, JM, Lindholm E, Anthony LB, Boudreaux JP, Woltering EA, Wang YZ. Application of Sentinel Lymph Node Mapping in Abdominal Carcinoid Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. (2008)

27. Lyons JM, Abergel J, Wang YZ, Anthony LB, Boudreaux JP, Warner RRP, Woltering EA: In-Vitro Analysis of Chemo-resistance in Patients with “Typical” and “Atypical” Carcinoid Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. (2008)

28. Lyons, III JM, Abergel J, Thomson JL, Wang YZ, Anthony LB, Boudreaux

JP, Strauchen J, Idrees M, Warner RRP, Woltering EA: In vitro chemoresistance testing in well differentiated carcinoid tumors. The Society of Surgical Oncology 61st Annual Cancer Symposium. Chicago, IL. (2008)

29. Lyons, III JM, Lindholm E, Boudreaux JP, Anthony LB, Woltering EA, Wang YZ. Diaphragmatic Implants In Patients With Metastatic Carcinoid.  The Society of Surgical Oncology 62nd Annual Cancer Symposium. Phoenix, AZ. (2009).

30. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA. Lymphatic mapping helps define resection margins for midgut carcinoids. AAES (American Association of Endocrine Surgeons) annual Meeting. Madison, WI. (2009)

31. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA. Lymphatic mapping helps define resection margins for midgut carcinoids.

Neuroendocrine Patient Conference. New Orleans LA. (2009)32. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA.

Lymphatic mapping helps define resection margins for midgut carcinoids. NANETS annual Meeting. (2009)

33. Lyons JM III, Lindholm E, Wang YZ, Thomson JL, Anthony LB, Woltering EA, Frey DJ, Joseph S, Ramacharan T and Boudreaux JP. Extensive retroperitoneal carcinoid involving the mesenteric vasculature does not preclude effective cytoreduction. NANETS annual Meeting. (2009)

34. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R and Woltering EA. Initial evaluation of patients with NETS: A prospective evaluation of intensive pre-visit counseling. NANETS annual Meeting. (2009)

35. Lyons III JM , Lindholm E, Thomson JL , Anthony LB, Woltering EA, Frey DJ, Joseph S, Ramacharan T, Wang YZ and Boudreaux JP. Extensive retroperitoneal carcinoid involving the mesenteric vasculature does not preclude effective cytoreduction. LA Chapter of American College of Surgeons. (2010)

36. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R and Woltering EA. Initial evaluation of patients with NETS: A prospective evaluation of intensive pre-visit counseling. LA Chapter of American College of Surgeons. (2010)

37. Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. LA Chapter of American College of Surgeons. New Orleans, LA. (2010)

38. Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. AAES. Pittsburgh, PA. (2010)

39. Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. NANETS Conference. Santé Fe, NM. (2010)

40. Wang YZ, Woltering E, and Boudreaux JP. Staged second-look laparoscopy to evaluate ischemic bowel following extensive mesenteric lymphadenectomy for midgut carcinoid. NANETS Conference. Santé Fe, NM. (2010)

41. Campeau RJ, Anthony LB, Woltering EA, Wang YZ, and Boudreaux JP. Short Term Response to Systemic I-131 MIBG Therapy in Metastatic Carcinoid Tumors. NANETS Conference. Santé Fe, NM. (2010)

42. Lindholm EB, Anthony C, Boudreaux JP, Gandolfi A, Ryan P, Wang YZ, Woltering EA. Are Primary Tumors and Metastatic Tumors the Same? NANETS Conference. Santé Fe, NM. (2010)

43. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. American College of Surgeons Clinical Congress, San Francisco, CA. (2011)

44. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. NANETS Conference, Minneapolis, MN. (2011)

45. Woltering EA, Diebold AE, Wang YZ, Anthony LA, Boudreaux JP, Uhlhorn AP, Ryan P, Burns LAK, Frey D, Raines D, Majoria R, and Campeau R. Treatment of Small Bowel Neuroendocrine Tumors (NETs) in a Multidisciplinary Specialty Center Increases Survival. NANETS Conference, Minneapolis, MN. (2011)

46. Diebold AE, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, and Woltering EA. Neurokinin A Levels Predict Survival in Patients with Well Differentiated Small Bowel Neuroendocrine Tumors (NETs). NANETS Conference, Minneapolis, MN. (2011)

47. King H, Wang YZ. Cocoon Formation in Patients with Mid-Gut Neuroendocrine Tumors: A Rare and Unrecognized Final Pathway. NANETS Conference, Minneapolis, MN. (2011)

48. Jahangir KS, Majoria R, Hagan J, Boudreaux J, Wang YZ, Boulmay B, Campeau R, Woltering E, and Anthony L. Hepatic Artery Radioembolization (HARE) in the Management of Progressive Metastatic Neuroendocrine Tumors (NETs): A Survival and Biochemical Response Analysis in Geriatric (G) and Young (Y) Populations. NANETS Conference, Minneapolis, MN. (2011)

49. Wang YZ and Hall M. Obturator canal lymph node metastasis from rectal carcinoid tumor---Total mesorectal excision may be insufficient for some rectal carcinoids. ASCO/2012 Gastrointestinal cancer symposium, San Francisco, California. (2012)

50. Wang YZ, Diebold A, Boudreaux JP, Raines D, Campeau R, Anthony L and Woltering E. Surgical treatment options for rectal carcinoid cancer: Trans-anal excision Versus Low Anterior Resection with Total Mesorectal Excision. Oral presentation, SAGES annual meeting. San Diego, California. (2012)

51. Wang YZ. King H. Cocoon Formation in Patients with Mid-Gut Neuroendocrine Tumors: A Rare and Unrecognized Final Pathway. SAGES annual meeting. San Diego, California. (2012)

52. Wang YZ and Hall M. Obturator canal lymph node metastasis from rectal carcinoid tumor---Total mesorectal excision may be insufficient for some rectal carcinoids. Society of Surgical Oncology’s 65th annual cancer symposium, Orlando, Florida. (2012)

53. Diebold AE, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, and Woltering EA. Neurokinin A Levels Predict Survival in Patients with Well Differentiated Small Bowel Neuroendocrine Tumors (NETs). AAES Annual Meeting. Iowa City, IA. (2012)

54. Wang YZ, Diebold A, Boudreaux P, Campeau R, Anthony L and Woltering E. Ovarian Metastasis from Midgut Neuroendocrine Tumors: Incidence, Clinical Implications and Management Options. American College of Surgeons Annual Meeting. Chicago, IL. (2012)

55. Wang YZ, Diebold A, Boudreaux P, Raines D, Anthony L, Woltering E. Surgical Treatment Options for Rectal Carcinoid Cancer: Trans-Anal Excision versus Low Anterior Resection with Total Mesorectal Excision. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. San Diego, CA. (2012)

56. Boudreaux JP, Diebold AE, Wang YZ, Woltering EA. Resection of Liver Metastasis in Midgut Neuroendocrine Tumors Affects 10-Year Survival. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. San Diego, CA. (2012)

57. Boudreaux JP, Wang YZ, Diebold AE, Woltering EA. Lymph Node Positivity in Patients with Small T1 and T2 Midgut Neuroendocrine Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. San Diego, CA. (2012)

58. Harkrider WW, Diebold AE, Maloney T, Espenan G, Wang YZ, Stafford SJ, Camp A, Frey D, Chappuis C, Woltering EA. An Extended Phase II Trial of 125-I Methylene Blue for Sentinel Lymph Node Identification in Women with Breast Cancer. Southern Surgical Association Annual Meeting. Palm Beach, FL. (2012)

59. Wang YZ, Rau J, Diebold AE, Opoku-Boateng A, Boudreaux JP, and Woltering EA. Neuroendocrine Tumors (NETs) of Unknown Primary: Is Early Surgical Exploration and Aggressive Debulking Justifiable? ASCO-GI Symposium. San Francisco, CA. (2013)

Invited Presentations and Seminars:1. Oral presentation, Lymphatic mapping helps define resection margins for

midgut carcinoids. AAES Meeting, Madison, WI (2009).2. Invited Speaker, Lymphatic mapping helps define resection margins for

midgut carcinoids. Neuroendocrine patient conference, New Orleans, LA (2009).

3. Oral presentation, Radioguided Exploration Facilitates Surgical Cytoreduction of Neuroendocrine Tumors. ACS Annual Chapter Meeting, New Orleans, LA (2010).

4. Invited speaker, Surgical treatment of Carcinoid- What’s new? Denver carcinoid cancer patients support group. Denver, CO (2010).

5. Invited speaker, Surgical treatment of Carcinoid- What’s new? NOIDS in the Carolinas carcinoid cancer patient support group. Charlotte, NC (2010).

6. Visiting professor/ Grand round, Surgical treatment of Carcinoid- What’s new? Mount Sinai Medical School/ Medical Center, New York, NY (2011).

7. Invited speaker, Surgical treatment of Carcinoid-What’s new? Virginia medical association, White Stone Creek, VA (2011).

8. Oral presentation, Surgical treatment options for rectal carcinoid cancer: Trans-anal excision versus low anterior resection with total mesorectal excision. SAGES annual meeting, San Diego, CA (2012).

9. Invited speaker, Surgical treatment of intestinal neuroendocrine tumors-What’s new & what’s next? CNETs Conference, Ontario, Canada (2012).

10. Invited speaker, Surgical treatment of intestinal neuroendocrine tumors-What’s new & what’s next? The Wellness House NET patient conference, Chicago, IL (2012).

11. Invited speaker, Surgical treatment of intestinal neuroendocrine tumors-What’s new & what’s next? MD Anderson Cancer Center, Orlando, FL (2012).

12. Invited speaker, Surgical treatment of intestinal neuroendocrine tumors-What’s new & what’s next? NET patient conference, New Orleans, LA (2012).

SERVICE ACTIVITIESUniversity/Institutional Service:

LSUHSC (campus) committees

Cancer Education Committee The Moses Maimonides Award for Ethics in Medicine CommitteeWomen Veterans Advisory Committee (Surgical Services)Careers in Medicine CourseCommittee in Residents’ Education

Clinical Service:In-patient service activitiesOn average, I conduct 2-5 major cyto-reductive surgeries (lymphatic mapping guided resection of small bowel primaries, extensive mesenteric lymphadenectomy to open the encased major mesenteric vessels, liver resection, retroperitoneal aorto-caval lymph node dissection, pancreatic or colorectal resection) a week. In the last five years I have performed more than 600 major surgeries for patients with neuroendocrine tumors. Clinic coverageCall

Administrative Responsibilities:Departmental Director of Surgical Education until 12/2005, Resident advisorSchool Student PreceptorHospital Member of the Pharmacy & Therapeutics/Infection Control Committee, Ochsner-Kenner Medical Center